Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial

Background: Tumour necrosis factor production is increased in the mucosa of patients with active ulcerative colitis. The benefits of infliximab in Crohn’s disease are established. We investigated its efficacy in ulcerative colitis. Methods: We conducted a randomised placebo controlled trial of infli...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Probert, C S J, Hearing, S D, Schreiber, S, Kühbacher, T, Ghosh, S, Arnott, I D R, Forbes, A
Формат: Artigo
Язык:Inglês
Опубликовано: Copyright 2003 by Gut 2003
Предметы:
Inflammatory Bowel Disease
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC1773722/
https://ncbi.nlm.nih.gov/pubmed/12801957
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы